.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

INTEGRILIN Drug Profile

« Back to Dashboard
Integrilin is a drug marketed by Schering and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in INTEGRILIN is eptifibatide. There are thirteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.

Summary for Tradename: INTEGRILIN

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998RXYes5,807,825► subscribe ► subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 1998RXYes5,807,825► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 19985,686,570► subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 19985,968,902► subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-002May 18, 19985,968,902► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INTEGRILIN

Drugname Dosage Strength RLD Submissiondate
eptifibatideInjection0.75 mg/mL, 100 mL vialIntegrilin6/5/2009
eptifibatideInjection2 mg/mL, 100 mL vialIntegrilin12/18/2008
eptifibatideInjection2 mg/mL, 10 mL vialIntegrilin9/30/2008

Non-Orange Book Patents for Tradename: INTEGRILIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,958,732 Platelet aggregation inhibitors► subscribe
5,756,451 Platelet aggregation inhibitors► subscribe
5,968,902 Platelet aggregation inhibitors► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INTEGRILIN

Country Document Number Estimated Expiration
Norway304267► subscribe
Norway982249► subscribe
Norway312965► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INTEGRILIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90043Netherlands► subscribePRODUCT NAME: EPTIFIBATIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 - EU/1/99/109/002 19990701; FIRST REGISTRATION: CH 54050, 54054 19970227
/1999Austria► subscribePRODUCT NAME: EPTIFIBATID ODER PHARMAZEUTISCH ANNEHMBARE SALZE HIEVON; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 EU/1/99/109/002 19990701; FIRST REGISTRATION: LI 54050 UND 54054 19970227
C/GB99/046United Kingdom► subscribePRODUCT NAME: EPTIFIBATIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: CH 54054 19970227; CH 54050 19970227; UK EU/1/99/109/001 19990701; UK EU/1/99/109/002 19990701
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc